The CD53 Knockout HAP1 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population specifically disrupting CD53 gene expression in the HAP1 cell line. This product delivers a heterogeneous pool of HAP1 cells carrying targeted gene disruptions in CD53, enabling loss-of-function studies without the limitations of single-cell clones. The CRISPR/Cas9-mediated gene targeting ensures efficient ablation of tetraspanin protein function, creating a reliable model for investigating CD53-dependent processes.
HAP1 cells are a near-haploid human cell line derived from a patient with chronic myeloid leukemia (CML). Their near-haploid karyotype simplifies genetic analysis and reduces interference from redundant alleles, making them exceptionally suited for knockout-based functional genomics. As a leukemic hematopoietic model, HAP1 cells retain core signaling networks involved in leukocyte biology and oncogenesis, facilitating mechanistic studies in a disease-relevant context.
CD53 is a cell surface tetraspanin that organizes specialized membrane microdomains to regulate leukocyte signal transduction, adhesion, and migration. It interacts directly with integrin LFA-1 and other tetraspanins such as CD9, CD81, CD82, and CD151. Upstream regulators include cytokines IL-2, IL-4, and GM-CSF, as well as B-cell and T-cell receptor (BCR/TCR) stimulation. Upon engagement, CD53 recruits and activates Src-family kinases Lyn and Fyn, which drive downstream PI3K/Akt and ERK1/2 signaling cascades, leading to enhanced integrin activation and cytoskeletal reorganization. CD53 also modulates NF-??B pathway activity, thereby connecting tetraspanin-mediated adhesion to transcriptional regulation of immune responses.
Within the HAP1 leukemic background, CD53 knockout allows unambiguous dissection of tetraspanin contributions to malignant cell behavior. Disruption of CD53 impairs the formation of tetraspanin-enriched membrane domains, resulting in compromised integrin-dependent adhesion and diminished chemokine-driven migration. This model is particularly valuable for studying hematologic malignancies where CD53 and associated tetraspanins influence disease progression. The polyclonal population preserves phenotypic diversity and avoids clonal selection biases, making it ideal for unbiased functional screens and comparative proteomics.
These polyclonal knockout cells are suitable for a broad array of experimental applications. Researchers can perform flow cytometry and Western blotting to confirm loss of CD53 protein, cell adhesion assays using integrin ligands, Transwell migration assays toward chemokines, co-immunoprecipitation with interacting partners such as CD45 and MHC class II, live-cell imaging, and phagocytosis assays. They support investigations into leukocyte signal transduction, immunological disorders, and cancer cell biology. For additional technical inquiries, please contact Ascent Research.
